Innate Pharma (IPHA) Income from Continuing Operations (2019 - 2025)
Innate Pharma's (IPHA) quarterly Income from Continuing Operations came in at 57244167.92 in Q4 2025, down 8.28% YoY from 62415096.26 in Q4 2024, and down 136.93% on a QoQ basis from 24160547.58 in Q2 2025.
Innate Pharma (IPHA) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of Income from Continuing Operations data on file, last reported at 57244167.92 in Q4 2025.
- Quarterly Income from Continuing Operations fell 8.28% year-over-year to 57244167.92 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 160937242.48 (down 84.86% YoY) and the FY2025 annual result came in at 57244167.92, down 8.28% from the prior year.
- Income from Continuing Operations slipped to 57244167.92 in Q4 2025, from 24160547.58 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 618509.05 in Q2 2023 to a low of 57244167.92 in Q4 2025.
- A 5-year average of 29832854.05 and a median of 26668043.94 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations sank 5435.2% — and 2022, when it soared 69.37%.
- Tracing IPHA's Income from Continuing Operations over 5 years: stood at 54710410.74 in 2021, then soared by 69.37% to 16757562.98 in 2022, then jumped by 51.4% to 8144865.11 in 2023, then tumbled by 549.05% to 52864483.04 in 2024, then decreased by 8.28% to 57244167.92 in 2025.
- The last three Income from Continuing Operations figures came in at 57244167.92 (Q4 2025), 24160547.58 (Q2 2025), and 52864483.04 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 81.49 Mn |
| 10 | Innate Pharma | 202.48 Mn | 202.48 Mn | - | -57.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -57.24 Mn |
| Jun 30, 2025 | -24.16 Mn |
| Dec 31, 2024 | -52.86 Mn |
| Jun 30, 2024 | -26.67 Mn |
| Dec 31, 2023 | -8.14 Mn |
| Jun 30, 2023 | 618,509.05 |
| Dec 31, 2022 | -16.76 Mn |
| Dec 31, 2021 | -54.71 Mn |
| Jun 30, 2021 | -28.56 Mn |
| Dec 31, 2020 | -988,408.29 |
| Jun 30, 2020 | -11.38 Mn |
| Dec 31, 2019 | -22.98 Mn |